# A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer

> **NCT05871918** · PHASE3 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 832 (estimated)

## Conditions studied

- HER-2 Positive Breast Cancer

## Interventions

- **DRUG:** TCbHP VS ddEC-THP

## Key facts

- **NCT ID:** NCT05871918
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-08
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 832 (ESTIMATED)
- **Last updated:** 2023-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05871918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05871918, "A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05871918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*